LONDON, Feb 28, 2021 (BSS/TASS) – Russia’s Sputnik V COVID-19 vaccine has
produced strong results against new mutations of coronavirus, including its
UK and South African variants, Denis Logunov, a deputy director of Russia’s
Gamaleya National Research Center for Epidemiology and Microbiology which
developed Sputnik V, told Reuters.
“A recent study carried out by the Gamaleya Centre in Russia showed that
revaccination with Sputnik V vaccine is working very well against new
coronavirus mutations, including the UK and South African strains of
coronavirus,” he said adding that according to the Russian researchers
“believe that vector-based vaccines are actually better for future
revaccinations than vaccines based on other platforms.”
Reuters reported that results of the trial were expected to be published
soon.
Logunov said that the trial indicated that the revaccination did not impact
the effectiveness of the vaccine. According to the scientist, “the antibodies
specific to the vectors used by the shot – which could generate an anti-
vector reaction and undermine the work of the shot itself – waned ‘as early
as 56 days after vaccination’,” the agency said.
Russia was the first country to register its vaccine against the novel
coronavirus on August 11, 2020. The Sputnik V vaccine was developed by the
Gamaleya National Research Center for Epidemiology and Microbiology of the
Russian Health Ministry. Sputnik V is a vaccine on a human adenoviral vector-
based platform. The two-part vaccine is administered in two doses.